Encyclopaedic Review of Glipizide Pre-clinical and Clinical
Status
In conclusion, glipizide has shown promising
therapeutic efficacy across a variety of disorders. [...] Georg Thieme Verlag Rüdigerstraße 14, 70469 Stuttgart,
GermanyArticle in Thieme eJournals: Table of contents | Abstract | Full text (Source: Drug Research)
Source: Drug Research - February 26, 2024 Category: Drugs & Pharmacology Authors: Mohammad, Saad Mahmood, Tarique Shamim, Arshiya Ahsan, Farogh Shariq, Mohammad Parveen, Saba Waseem, Rufaida Singh, Aditya Tags: Review Source Type: research
Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations
Curr Pain Headache Rep. 2023 Aug 16. doi: 10.1007/s11916-023-01151-0. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Although the association between CGRP and migraine disease is well-known and studied, therapies can target other pathways to minimize migraine symptoms. It is important to understand the role of these medications as options for migraine treatment and the varied mechanisms by which symptoms can be addressed. In the present investigation, the role of non-CGRP antagonist/non-triptan options for migraine disease therapy is reviewed, including NSAIDs, ß-blockers, calcium channel blockers, antidepressants, and ...
Source: Pain Physician - August 16, 2023 Category: Anesthesiology Authors: Ellen E Ingram Brooke E Bocklud Sarah C Corley Mallory A Granier Elisa E Neuchat Shahab Ahmadzadeh Sahar Shekoohi Alan D Kaye Source Type: research
Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations
Curr Pain Headache Rep. 2023 Aug 16. doi: 10.1007/s11916-023-01151-0. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: Although the association between CGRP and migraine disease is well-known and studied, therapies can target other pathways to minimize migraine symptoms. It is important to understand the role of these medications as options for migraine treatment and the varied mechanisms by which symptoms can be addressed. In the present investigation, the role of non-CGRP antagonist/non-triptan options for migraine disease therapy is reviewed, including NSAIDs, ß-blockers, calcium channel blockers, antidepressants, and ...
Source: Pain Physician - August 16, 2023 Category: Anesthesiology Authors: Ellen E Ingram Brooke E Bocklud Sarah C Corley Mallory A Granier Elisa E Neuchat Shahab Ahmadzadeh Sahar Shekoohi Alan D Kaye Source Type: research
Non-CGRP Antagonist/Non-Triptan Options for Migraine Disease Treatment: Clinical Considerations
AbstractPurpose of ReviewAlthough the association between CGRP and migraine disease is well-known and studied, therapies can target other pathways to minimize migraine symptoms. It is important to understand the role of these medications as options for migraine treatment and the varied mechanisms by which symptoms can be addressed. In the present investigation, the role of non-CGRP antagonist/non-triptan options for migraine disease therapy is reviewed, including NSAIDs, ß-blockers, calcium channel blockers, antidepressants, and antiepileptics. Pharmacologic therapies for both acute symptoms and prophylaxis are evaluated,...
Source: Current Pain and Headache Reports - August 16, 2023 Category: Neurology Source Type: research
Tolerability of pharmacological agents in the treatment of headache following brain injury: a scoping review
CONCLUSION: The unique needs of people with TBI must be considered when instituting pharmacotherapy. More studies specifically evaluating medication tolerability in PTH are needed.PMID:36637191 | DOI:10.1080/02699052.2023.2165156 (Source: Brain Injury)
Source: Brain Injury - January 13, 2023 Category: Neurology Authors: Heather M MacKenzie Michael Robinson Amanda McIntyre Source Type: research
Fixed Dose Combination Tablets of Aripiprazole and Divalproex Sodium: a Pilot Pharmacokinetic Study in Human Volunteers
AAPS PharmSciTech. 2022 Aug 19;23(7):232. doi: 10.1208/s12249-022-02378-7.ABSTRACTA combination product of aripiprazole (antipsychotic) and divalproex sodium (mood stabilizer) was recently developed to establish their tolerability and safety in fixed dose combination (FDC). A pilot pharmacokinetic (PK) open-labeled parallel study on healthy human volunteers was carried out to assess the PK of FDC of aripiprazole/divalproex sodium in comparison with its individual components with a view to rationalize therapeutic regimen and potentially improve compliance of bipolar patients in future. A total of 24 volunteers were randomiz...
Source: AAPS PharmSciTech - August 19, 2022 Category: Drugs & Pharmacology Authors: Zia Ahmed Fazal Subhan Saba Ahmed Source Type: research
Fixed Dose Combination Tablets of Aripiprazole and Divalproex Sodium: a Pilot Pharmacokinetic Study in Human Volunteers
AAPS PharmSciTech. 2022 Aug 19;23(7):232. doi: 10.1208/s12249-022-02378-7.ABSTRACTA combination product of aripiprazole (antipsychotic) and divalproex sodium (mood stabilizer) was recently developed to establish their tolerability and safety in fixed dose combination (FDC). A pilot pharmacokinetic (PK) open-labeled parallel study on healthy human volunteers was carried out to assess the PK of FDC of aripiprazole/divalproex sodium in comparison with its individual components with a view to rationalize therapeutic regimen and potentially improve compliance of bipolar patients in future. A total of 24 volunteers were randomiz...
Source: AAPS PharmSciTech - August 19, 2022 Category: Drugs & Pharmacology Authors: Zia Ahmed Fazal Subhan Saba Ahmed Source Type: research
Fixed Dose Combination Tablets of Aripiprazole and Divalproex Sodium: a Pilot Pharmacokinetic Study in Human Volunteers
AAPS PharmSciTech. 2022 Aug 19;23(7):232. doi: 10.1208/s12249-022-02378-7.ABSTRACTA combination product of aripiprazole (antipsychotic) and divalproex sodium (mood stabilizer) was recently developed to establish their tolerability and safety in fixed dose combination (FDC). A pilot pharmacokinetic (PK) open-labeled parallel study on healthy human volunteers was carried out to assess the PK of FDC of aripiprazole/divalproex sodium in comparison with its individual components with a view to rationalize therapeutic regimen and potentially improve compliance of bipolar patients in future. A total of 24 volunteers were randomiz...
Source: AAPS PharmSciTech - August 19, 2022 Category: Drugs & Pharmacology Authors: Zia Ahmed Fazal Subhan Saba Ahmed Source Type: research
Fixed Dose Combination Tablets of Aripiprazole and Divalproex Sodium: a Pilot Pharmacokinetic Study in Human Volunteers
AAPS PharmSciTech. 2022 Aug 19;23(7):232. doi: 10.1208/s12249-022-02378-7.ABSTRACTA combination product of aripiprazole (antipsychotic) and divalproex sodium (mood stabilizer) was recently developed to establish their tolerability and safety in fixed dose combination (FDC). A pilot pharmacokinetic (PK) open-labeled parallel study on healthy human volunteers was carried out to assess the PK of FDC of aripiprazole/divalproex sodium in comparison with its individual components with a view to rationalize therapeutic regimen and potentially improve compliance of bipolar patients in future. A total of 24 volunteers were randomiz...
Source: AAPS PharmSciTech - August 19, 2022 Category: Drugs & Pharmacology Authors: Zia Ahmed Fazal Subhan Saba Ahmed Source Type: research
Valproate: Not All Boxed Warnings Are Created Equal
CONCLUSIONS: Overstated monitoring recommendations for the potential risk of hepatotoxicity and pancreatitis distracts from a much more common and severe risk of fetal harm. Clinicians must be diligent about discussing this risk with patients and documenting when this discussion occurs. Changes to the current recommendations for monitoring of the boxed warnings associated with valproate therapy should be considered, such as more stringent monitoring requirements for the inherent fetal risk. This could be accomplished through a Risk Evaluation and Mitigation Strategy program or through institution-based policies and procedu...
Source: The Annals of Pharmacotherapy - April 8, 2022 Category: Drugs & Pharmacology Authors: Carolanne Wartman Amy VandenBerg Source Type: research
Valproate: Not All Boxed Warnings Are Created Equal
CONCLUSIONS: Overstated monitoring recommendations for the potential risk of hepatotoxicity and pancreatitis distracts from a much more common and severe risk of fetal harm. Clinicians must be diligent about discussing this risk with patients and documenting when this discussion occurs. Changes to the current recommendations for monitoring of the boxed warnings associated with valproate therapy should be considered, such as more stringent monitoring requirements for the inherent fetal risk. This could be accomplished through a Risk Evaluation and Mitigation Strategy program or through institution-based policies and procedu...
Source: The Annals of Pharmacotherapy - April 8, 2022 Category: Drugs & Pharmacology Authors: Carolanne Wartman Amy VandenBerg Source Type: research
